Pharmaceuticals Sector Partnerships, Licensing, Investments Mergers and Acquisitions Deals and Trends for April 2020

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for April 2020 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

1. Table of Contents 2

1.1. List of Tables 5

1.2. List of Figures 7

2. Deal Values in Pharmaceutical and Healthcare Industry Decreased in April 2020 9

2.1. Pharmaceuticals & Healthcare, Deals Summary, April 2020 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13

3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2020 13

3.2. Pharmaceuticals & Healthcare, Global, Major Deals, April 2020 14

3.2.1. Fate Therapeutics Enters into Co-Development Agreement with Janssen Biotech 15

3.2.2. Biogen Prices Public Offering of Senior Unsecured Notes for USD3 Billion 15

3.2.3. Vertex Pharma Enters into Licensing Agreement with Affinia Therapeutics 15

3.2.4. Eli Lilly Raises USD1.08 Billion in Public Offering of

2.25% Notes Due 2050 16

3.2.5. Blackstone Life Sciences to Acquire 50% Royalties and Commercial Milestones of Inclisiran from Alnylam Pharma 16

3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2020 18

3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2020 19

4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

4.1. Pharmaceuticals & Healthcare, Global, M&A, April 2020 20

4.1.1. Top M&A Deals in April 2020 21

4.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2019– April 2020 22

4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2020 23

4.2.1. Top Equity Offering Deals in April 2020 24

4.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2019– April 2020 25

4.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2020 26

4.3.1. Top PE/VC Deals in April 2020 27

4.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2020 28

4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2020 29

4.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, November 2019–April 2020 31

4.3.7. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2019–April 2020 33

4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2020 34

4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2019– April 2020 36

4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2020 37

4.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2020 38

4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 39

4.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2019– April 2020 41

4.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2019– April 2020 42

4.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2019– April 2020 44

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2020 46

5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2020 46

5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2020 48

5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2019– April 2020 50

5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2019– April 2020 52

5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2019– April 2020 54

5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2019– April 2020 57

5.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2020 58

5.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2020 59

5.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2020 60

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 61

6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2020 61

6.1.1. Oncology – Deals of the Month 62

6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2020 64

6.2.1. Central Nervous System – Deals of the Month 65

6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2020 66

6.3.1. Infectious Diseases – Deals of the Month 67

6.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2020 69

6.4.1. Cardiovascular – Deals of the Month 70

6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2020 72

6.5.1. Immunology – Deal of the Month 73

6.6. Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, April 2020 75

6.6.1. Metabolic– Deals of the Month 76

6.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, April 2020 78

6.7.1. Gastrointestinal – Deals of the Month 79

7. Deal Summary by Geography 80

7.1. Pharmaceuticals & Healthcare, North America Deals, April 2020 80

7.1.1. North America – Deals of the Month 81

7.2. Pharmaceuticals & Healthcare, Europe, Deals, April 2020 84

7.2.1. Europe – Deals of the Month 85

7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2020 87

7.3.1. Asia-Pacific – Deals of the Month 88

7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2020 90

7.4.1. Rest of the World – Deals of the Month 91

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 93

8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2019– April 2020 93

8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2019– April 2020 95

9. Further Information 97

9.1. Methodology 97

9.2. About GlobalData 98

9.3. Contact Us 98

9.4. Disclosure information 98

9.5. Disclaimer 98

List of Tables

1.1. List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 14

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2020 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2020 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2020 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2019– April 2020 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2020 24

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 25

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 27

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2020 27

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2019– April 2020 28

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2020 30

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2019– April 2020 31

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2019– April 2020 32

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2019– April 2020 33

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2019– April 2020 34

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 35

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2020 36

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 38

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2019– April 2020 41

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2019– April 2020 43

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 45

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 47

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2019– April 2020 49

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2020 51

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, November 2019– April 2020 54

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2020 56

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2020 56

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2020 57

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2020 58

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 60

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 63

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 65

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 68

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 71

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 74

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 77

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 79

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 83

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 86

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 89

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2019– April 2020 92

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2019– April 2020 94

List of Figures

1.2. List of Figures

s

Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, April 2020 9

Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, November 2019 – April 2020 10

Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, April 2020 11

Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, April 2020 12

Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2019– April 2020 13

Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), April 2020 18

Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2020 19

Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2019– April 2020 20

Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2019– April 2020 22

Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2019– April 2020 23

Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2019– April 2020 25

Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2019– April 2020 26

Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2019– April 2020 28

Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), April 2020 29

Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2020 30

Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2019– April 2020 31

Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2019– April 2020 34

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2019– April 2020 36

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 37

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 39

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2019– April 2020 41

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2019– April 2020 42

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2019– April 2020 44

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2019– April 2020 46

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 48

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2019– April 2020 50

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2019– April 2020 52

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, November 2019– April 2020 54

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2019– April 2020 55

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2020 57

Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2019– April 2020 61

Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2019– April 2020 64

Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2019– April 2020 66

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2019– April 2020 69

Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2019– April 2020 72

Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 75

Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2019– April 2020 78

Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2019– April 2020 80

Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2019– April 2020 84

Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2019– April 2020 87

Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2019– April 2020 90

Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2019– April 2020 93

Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2019– April 2020 95

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports